We described the clinical outcome of 17 patients with secondary Acinetobacter bacteremia, whose isolates had a tigecycline minimal inhibitory concentration of </= 2mg/L and that received tigecycline within 2 days of bacteremia onset. Fourteen-day mortality rate of tigecycline cohort was 41.2% (7/17), which was significantly higher than those receiving other appropriate antimicrobial agents (13.8%, 9/65, P=0.018). However, the percentages of end-stage renal disease and congestive heart failure were higher in the tigecycline cohort. Efficacy of tigecycline was contingent upon the illness severity and bacterial species. Tigecycline should be applied cautiously for treatment of Acinetobacter bacteremia.
Date:
2015-06
Relation:
Antimicrobial Agents and Chemotherapy. 2015 Jun;59(6):3637-3640.
